Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

16.64 +0.08 (+0.45%)
Streaming Delayed Price Updated: 11:09 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 ↗
Takeda Pharmaceutical just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder ↗
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
News headline image
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win ↗
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
News headline image
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
News headline image
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Hot List: 3 AI Stocks Worth Buying on Weakness ↗
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus ↗
Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies. 
Via Benzinga
News headline image
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study ↗
Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024. 
Via Benzinga
News headline image
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? ↗
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated. 
Via Benzinga
News headline image
Takeda Announces Chief Financial Officer Succession
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Earnings Scheduled For February 1, 2024 ↗
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
News headline image
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
3 Stocks to Buy to Benefit From the Booming Sleep Industry ↗
It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation. 
Via InvestorPlace
News headline image
Takeda Named Global Top Employer for Seventh Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.